Content and data provided by various third parties and Fidelity − Terms of Use

Stock Details

RELATED RESOURCES

News & Events:ABMD

ABIOMED INC

235.75Down -2.90 (-1.2152 %)as of 4:00:00pm ET 05/20/2022

Quotes delayed at least 15 min. Log in for real time quote.

Log in for more news Show all article details.Expand all| Hide all article details.Collapse all
  1. Show article details.

    SCAI 2022 Scientific Sessions Highlight Impella Research, Advancements to Improve Cardiogenic Shock Outcomes

    Business Wire – 8:03 AM ET 05/18/2022

    Abiomed (ABMD), a leader in breakthrough heart, lung and kidney support technologies, will feature the most recent Impella research and technological advances aimed at improving outcomes for acute myocardial infarction cardiogenic shock patients during the Society for Cardiovascular Angiography and Interventions 2022 Scientific Sessions, May 19 – 22, in Atlanta. This press release features multimedia.
  2. Show article details.

    Recap: Abiomed Q4 Earnings

    Benzinga – 9:54 AM ET 04/28/2022

      Abiomed reported its Q4 earnings results on Thursday, April 28, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Abiomed beat estimated earnings by 6.42%, reporting an EPS of $1.16 versus an estimate of $1.09. Revenue was up $28.60 million from the same period last year.
  3. Show article details.

    BRIEF-Abiomed Announces Fourth Quarter Revenue Of $270 Mln

    Reuters – 7:15 AM ET 04/28/2022

    ABIOMED Inc (ABMD): * ABIOMED ANNOUNCES FOURTH QUARTER RECORD REVENUE OF $270 MILLION, UP 12% YEAR OVER YEAR. * Q4 NON-GAAP EARNINGS PER SHARE $1.16. * Q4 GAAP EARNINGS PER SHARE $1.31. * Q4 REVENUE ROSE 12 PERCENT TO $270 MILLION. * ANTICIPATES FISCAL YEAR 2023 GLOBAL REVENUE TO BE IN RANGE OF $1.14 BILLION TO $1.18 BILLION. * FY2023 REVENUE VIEW $1.17 BILLION -- REFINITIV IBES DATA.
  4. Show article details.

    Abiomed Announces Fourth Quarter Record Revenue of $270 Million, up 12% Year Over Year

    Business Wire – 7:00 AM ET 04/28/2022

    FY 2022 Annual Revenue of $1.032 billion, Up 22% Versus Prior Year ABIOMED, Inc. (ABMD), a leader in breakthrough heart, lung and kidney support technologies, today announced financial results for the quarter and fiscal year ended March 31, 2022.
  5. Show article details.

    Earnings Scheduled For April 28, 2022

    Benzinga – 4:50 AM ET 04/28/2022

      ** PBF Energy is projected to report quarterly earnings at $0.26 per share on revenue of $8.24 billion. ** Merck & Co is estimated to report quarterly earnings at $1.83 per share on revenue of $14.68 billion. ** Smith & Nephew is estimated to report earnings for its first quarter. ** Domino's Pizza is estimated to report quarterly earnings at $3.05 per share on revenue of $1.03 billion.
  6. Show article details.

    A Preview Of Abiomed's Earnings

    Benzinga – 2:02 PM ET 04/27/2022

    Abiomed is set to give its latest quarterly earnings report on Thursday, 2022-04-28. Analysts estimate that Abiomed will report an earnings per share of $1.09. Abiomed bulls will hope to hear the company to announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
  7. Show article details.

    World’s First Patient Implanted with Impella BTR Minimally Invasive Heart Pump

    Business Wire – 8:02 AM ET 04/26/2022

    Abiomed (ABMD) announces the first patient in the world has been successfully implanted with Impella Bridge-to-Recovery as part of the heart pump’s U.S. Food and Drug Administration Early Feasibility Study. Impella BTR, a forward flow heart pump that is implanted via the axillary artery and sits in the left ventricle, can pump greater than six liters of blood per minute.
  8. Show article details.

    Markets Rise Despite Another New 2-Year High For US 10-Year Treasury Note

    Benzinga – 4:20 PM ET 04/19/2022

    U.S. indices traded higher Tuesday on continued volatility as traders assess Fed policy outlook, rising Treasury yields and quarterly earnings reports. Here are the day's winners and losers from the S&P 500, according to data from Benzinga Pro. ABIOMED, Inc., Generac Holdings Inc. and Citizens Financial Group Inc were among the top gainers for the SPY.
  9. Show article details.

    Abiomed Fourth Quarter Fiscal 2022 Earnings and Conference Call Notification

    Business Wire – 7:00 AM ET 04/08/2022

    Abiomed, Inc (ABMD). announced that on Thursday, April 28, 2022, the Company will release financial results for the fourth quarter of the fiscal year 2022. To listen to the call live, please tune into the webcast via https://investors.abiomed.com/events-presentations or dial 200-6205; the international number is 526-1599 access code 660077.
  10. Show article details.

    What 4 Analyst Ratings Have To Say About Abiomed

    Benzinga – 2:04 PM ET 04/06/2022

    Abiomed has observed the following analyst ratings within the last quarter: In the last 3 months, 4 analysts have offered 12-month price targets for Abiomed. Below is a summary of how these 4 analysts rated Abiomed over the past 3 months.
  11. Show article details.

    Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2022

    Benzinga – 10:16 AM ET 04/06/2022

    According to Morgan Stanley, the prior rating for Royalty Pharma PLC was changed from Equal-Weight to Overweight. According to Keefe, Bruyette & Woods, the prior rating for PJT Partners Inc was changed from Market Perform to Outperform. Guggenheim upgraded the previous rating for Array Technologies Inc from Neutral to Buy.
  12. Show article details.

    First Patient in Japan Treated with Impella 5.5 with SmartAssist

    Business Wire – 8:04 AM ET 04/06/2022

    5,000 Patients Treated Globally The versatility and innovation of Abiomed’s Impella 5.5 with SmartAssist, a minimally-invasive forward flow heart pump, is leading to continued adoption of the game-changing technology by surgeons around the world. This press release features multimedia.
  13. Show article details.

    Abiomed to Host Investor Call on Impella ECP, the World’s Smallest Heart Pump at 9 French

    Business Wire – 7:00 AM ET 03/21/2022

    Abiomed, Inc (ABMD). today announced that it will host an investor call on Impella ECP on March 29, 2022 from 4:00 p.m. – 5:00 p.m. EDT. A live video webcast of the event will be available March 29 via the link https://events.abiomed.com/ImpellaECP.
Page:

Today's and Upcoming Events

  • Aug
    03

    ABMD to announce Q1 earnings (Unconfirmed)

Past Events (last 90 days)

  • Apr
    28

    ABMD announced Q4 earnings.

Data provided by Thomson Reuters © 2022

Technical Events

Classic Patterns (past 90 days)

PROVIDED BY RECOGNIA, INC.

View All Technical Analysis in Advanced Chart Opens in New Window

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.

Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
Copyright 1998–2022 FMR LLC. 
All rights reserved. 
Close
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.